Form 8-K Terns Pharmaceuticals, For: Sep 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Terns Pharmaceuticals (TERN) PT Raised to $30 at Jefferies Following +16% Gain Today
September 9, 2024 4:00 PM EDTJefferies analyst Akash Tewari raised the price target on Terns Pharmaceuticals (NASDAQ: TERN) to $30.00 (from $22.00) while maintaining a Buy rating.
The analyst comments "TERN-601 Ph1 readout in-line w/ our bull case: ~5% pbo-adj WL & ~88% nausea/~78% vomiting at the highest 740mg qd dose.... More
